{
    "2020-03-31": [
        [
            {
                "time": "2018-01-02",
                "original_text": "The Zacks Analyst Blog Highlights: Novartis, Teva, Gilead and AbbVie",
                "features": {
                    "keywords": [
                        "Zacks",
                        "Analyst Blog",
                        "Novartis",
                        "Teva",
                        "Gilead",
                        "AbbVie"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "The Biggest Biotech Is Expected To Grow â€” But Is It Enough To Be A Buy?",
                "features": {
                    "keywords": [
                        "Biggest Biotech",
                        "Expected To Grow",
                        "Buy"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}